Last updated 8 days ago
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
900 patients around the world
Available in United States, Brazil
Hoffmann-La Roche
1Research sites
900Patients around the world
This study is for people with
Extrapyramidal and movement disorders
Parkinson's disease
Requirements for the patient
To 85 Years
All Gender
Medical requirements
- Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2.Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria.Has received monotherapy treatment.An MDS-UPDRS Part IV score of 0 at screening and prior to randomization.Hoehn and Yahr (H&Y) Stage 1 or 2 off medication at screening and prior to randomization.Agreement to adhere to the contraception requirements.
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required.Medical history indicating a parkinsonian syndrome other than idiopathic PD.Diagnosis of a significant neurologic disease other than PD.Chronic uncontrolled hypertension.
Sites
CPClin – Centro de Pesquisas Clinicas LTDA
Recruiting
StudyPARAISO
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Parkinson's disease
Requirements
To 85 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07174310
